左氧氟沙星联合甲硝唑对慢性盆腔炎患者的炎症因子水平及安全性的影响

目的探讨左氧氟沙星与甲硝唑联用对慢性盆腔炎患者的安全性、疗效及炎症因子水平的影响。方法 100例慢性盆腔炎患者,按治疗方法的不同分为对照组和观察组,每组50例。对照组患者给予左氧氟沙星胶囊治疗,观察组患者在对照组基础上加用甲硝唑片治疗。比较两组患者治疗前后各炎症因子全血白细胞计数(WBC)、中性粒细胞绝对值(NEUT#)、中性粒细胞百分比(NEUT%)、降钙素原(PCT)、C反应蛋白(CRP)]水平的变化情况、临床效果以及治疗期间不良反应发生情况。结果治疗后,观察组WBC、NEUT#、NEUT%、PCT、CRP分别为(6.35±0.90)×10^9/L、(5.60±1.20)×10^9/L、(58.00±2.10)%、(0.11±0.02)ng/L、(5.46±1.32)mg/L,对照组分别为(7.50±1.20)×10^9/L、(6.20±1.30)×10^9/L、(60.00±3.60)%、(0.18±0.12)ng/L、(6.32±1.26)mg/L;两组WBC、NEUT#、NEUT%、PCT、CRP均较治疗前降低,且观察组降低幅度大于对照组,差异均有统计学意义(P<0.05)。观察组不良反应发生率8.0%与对照组的6.0%比较,差异无统计学意义(P>0.05)。观察组治疗总有效率96.0%高于对照组的84.0%,差异有统计学意义(P<0.05)。结论左氧氟沙星联合甲硝唑治疗慢性盆腔炎的疗效较为确切,明显改善了机体炎症因子水平,且安全性较高。

Effects of levofloxacin combined with metronidazole on inflammatory factor levels and safety in patients with chronic pelvic inflammation

Objective To discuss the safety and efficacy of levofloxacin combined with metronidazole in patients with chronic pelvic inflammation and its effect on inflammatory factors. Methods A total of 100 patients with chronic pelvic inflammation were divided into control group and observation group by different treatment methods, with 50 cases in each group. The control group was treated by levofloxacin capsule, and the observation group was treated by metronidazole tablets on the basis of the control group. The changes of inflammatory factors white blood cell count(WBC), absolute neutrophil count(NEUT #), neutrophil percentage(NEUT%), procalcitonin(PCT), C-reactive protein(CRP)] before and after treatment, clinical effect and occurrence of adverse reactions during treatment were compared between the two groups. Results After treatment, the levels of WBC, NEUT#, NEUT%, PCT and CRP of the observation group were(6.35±0.90)×10~9/L,(5.60±1.20)×10~9/L,(58.00±2.10)%,(0.11±0.02)ng/L and(5.46±1.32)mg/L, which were(7.50±1.20)×10~9/L,(6.20±1.30)×10~9/L,(60.00±3.60)%,(0.18±0.12) ng/L and(6.32±1.26) mg/L in the control group. The levels of WBC, NEUT#, NEUT%, PCT and CRP of the two groups were lower than those before treatment, and the decrease of the observation group was greater than that of the control group. The difference was statistically significant(P<0.05). The incidence of adverse reactions 8.0% of the observation group had no statistically significant difference compared with that of the control group(P>0.05). The total effective rate of treatment 96.0% of the observation group was higher than that of the control group 84.0%, and the difference was statistically significant(P<0.05). Conclusion Levofloxacin combined with metronidazole shows affirmative efficacy on the treatment of chronic pelvic inflammation, and it can obviously improve the inflammatory factor levels with high safety.